CERS · Cerus Corp
United States · RS rating 66 · As of 2026-11-03
| Price | 2.34 USD |
|---|---|
| 1-day change | -0.8% |
| RS rating (overall / 1M / 3M / 12M) | 66 / 56 / 73 / 88 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 30 / 29 / 17 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +9.6% |
| Distance from 52-week high | +28.7% |
| Market cap (USD) | $380.7M |